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Summary
Mithramycin and chromomycin A3 are two structurally
related antitumour compounds, which differ in the
glycosylation profiles and functional group substitu-
tions of the sugars. Chromomycin contains two acetyl
groups, which are incorporated during the biosynthe-
sis by the acetyltransferase CmmA in Streptomyces
griseus ssp. griseus. A bioconversion strategy using
an engineered S. griseus strain generated seven
novel acetylated mithramycins. The newly formed
compounds were purified and characterized by MS
and NMR. These new compounds differ from their
parental compounds in the presence of one, two or
three acetyl groups, attached at 3E, 4E and/or 4D
positions. All new mithramycin analogues showed
antitumour activity at micromolar of lower concentra-
tions. Some of the compounds showed improved
activities against glioblastoma or pancreas tumour
cells. The CmmA acetyltransferase was located in the
cell membrane and was shown to accept several acyl-
CoA substrates. All these results highlight the poten-
tial of CmmA as a tool to create structural diversity in
these antitumour compounds.
Introduction
Mithramycin 1 (Fig. 1) is an antitumour compound of the
aureolic acid family produced by Streptomyces argilla-
ceus (Rohr et al., 1999), which was discovered in 1961
and approved for use as anticancer drug in 1970
(Newman and Cragg, 2007). It has been used clinically for
the treatment of several types of cancer, including testicu-
lar carcinoma, chronic myeloid leukaemia and acute
myeloid leukaemia and also for the control of hypercal-
caemia in patients with malignant diseases (Remers,
1979; Skarbek and Speedie, 1981). More recently,
renewed interest for 1 is growing because of its potential
new applications. It has been found that 1 could be used
in combination with bevacizumab, a neutralizing antibody
against VEGF (Vascular Endothelial Growth Factor), as a
novel antiangiogenic therapy for pancreatic cancer and
other cancers (Jia et al., 2007). Moreover, 1 has revealed
to be a neuroprotective drug, possessing potential appli-
cation as neurological therapeutics, and for the alleviation
of symptoms underlying b-thalassaemia and sickle cell
anaemia due to its activity as inducer of erythrocitic cell
differentiation (Chatterjee et al., 2001; Fibach et al.,
2003). The antitumour properties of 1 are due to its inhibi-
tory effects on replication and transcription processes
during macromolecular biosynthesis by interacting, in the
presence of Mg2+, with GC-rich nucleotide sequences
located in the minor groove of DNA (Sastry and Patel,
1993; Sastry et al., 1995; Barcelo et al., 2007). As a con-
sequence it blocks the binding of proteins to GC-rich
sequences in gene promoters, and inhibits transcription of
genes regulated by these factors, such as those regulated
by the Sp1 family of transcription factors (Miller et al.,
1987; Ray et al., 1989; Blume et al., 1991; Snyder et al.,
1991).
Chromomycin A3 2 (Fig. 1) is an antitumour compound
structurally related to 1, but differing in the glycosylation
pattern. Mithramycin contains a trisaccharide of D-olivose,
D-oliose and D-mycarose, and a disaccharide of D-olivose,
while 2 contains a trisaccharide of D-olivose, D-olivose
and 4-O-acetyl-L-chromose B, and a disaccharide of 4-O-
acetyl-D-oliose and 4-O-methyl-D-oliose attached at posi-
tions 2 and 6 of the aglycone respectively. These
differences in the stereochemistry and functional group
substitutions of the sugars are expressed in the binding
properties of these compounds to DNA (Majee et al.,
1997; Mir et al., 2003). Thus, the acetoxy groups in
D-oliose (sugar A) and L-chromose B (sugar E) in 2
provide additional H-bonds with the 2-amino groups of
G-bases and thus adding more specificity to the DNA
binding (Silva and Kahne, 1993; Silva et al., 1993; Majee
et al., 1997; Chakrabarti et al., 2001). This is also shown
in their antitumour activities, where 2 is approximately 10
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times more active than 1 against several tumour cell lines
(Menéndez et al., 2004a; Pérez et al., 2008). We have
cloned and characterized the gene cluster involved in the
biosynthesis of 2 (Menéndez et al., 2004a,b; 2006; 2007).
It contains the cmmA gene, which encodes the acetyl-
transferase responsible for transferring both acetyl groups
to D-oliose and L-chromose B during 2 biosynthesis
(Menéndez et al., 2004b). Inactivation of cmmA leads to
the accumulation of 4A,4E-O-dideacetyl-chromomycin A3
(3) (Fig. 1), which differs from the parental compound by
lacking the two acetyl groups, and being approximately
100 times less active, which confirms the importance of
the acetyl groups for the antitumour activity of 2 (Menén-
dez et al., 2004b).
In this article we report the use of CmmA to increase the
structural diversity of mithramycins and to generate novel
mithramycins with antitumour activity. We also show that
CmmA is located in the cell membrane and exhibits
substrate flexibility using different acyl-CoAs as donor
substrates.
Fig. 1. Chemical structures of compounds
used as substrates in this work:
mithramycin 1, Chromomycin A3 2,
4A,4E-O-dideacetyl-chromomycin A3 3,
demycarosyl-mithramycin 4,
demycarosyl-3D-b-D-digitoxosyl-mithramycin
5, dideolivosyl-6-b-D-amicetosyl-mithramycin
6, deoliosyl-demycarosyl-3C-b-D-boivinosyl-
mithramycin 7, dideolivosyl-6-b-D-
amicetosyl-deoliosyl-3C-b-D-olivosyl-
mithramycin 8, mithramycin SK 9 and
mithramycin SDK 10.
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Results and discussion
Generation of acetylated analogues of mithramycin by
bioconversion
Two sugars (L-chromose B and one D-oliose) in 2 are
acetylated at the C4 hydroxyl groups (Fig. 1). These
acetyl groups are incorporated into the molecule by the
chromomycin acetyltransferase CmmA (Menéndez et al.,
2004b). Since these groups greatly increase the antitu-
mour activity of 2, we decided to use CmmA in order to
generate acetylated derivatives of 1 with high antitumour
activity. To achieve this, we performed a bioconversion
experiment by growing the wild-type strain Streptomyces
griseus ssp. griseus (chromomycin A3 producer) that was
subsequently fed with 1. These cultures were then
extracted and analysed by HPLC-MS. In addition to 1, a
new peak was detected showing the same absorption
spectrum than 1, but with higher retention time and an m/z
value in positive mode of 1128 (data not shown). This is in
agreement with compound 1 with one acetyl group
attached. We also tested if this acetylation event was
CmmA-dependent by running a bioconversion experiment
using S. griseus C10A as host (cmmA- mutant). No acety-
lated mithramycin was obtained in these conditions con-
firming that CmmA is required for this acetylation process
(data not shown). This result showed that CmmA was
flexible enough to be able to acetylate 1. The bioconver-
sion efficiency using the wild-type strain was rather low
(approximately 14%). Most probably this was due to the
fact that the acetyltransferase CmmA has more affinity to
its genuine substrate and/or was mainly committed to the
biosynthesis of 2. With the aim of improving the produc-
tion of acetylated derivatives of 1, we tested the biocon-
version efficiencies as biocatalysts of different mutant
strains of S. griseus affected in biosynthesis of 2. These
mutants (C60GI, C10GII, G10GIII and G10GIV; Fig. 2)
expressed the acetyltransferase CmmA but were blocked
in glycosylation steps taking place before the acetylation
of sugars, and therefore preventing the synthesis of
potential natural substrates for CmmA. When any of these
mutants was used in bioconversion experiments with 1 as
substrate, higher production of monoacetylated mithramy-
cin 11 was obtained. Since S. griseus C10GIV was more
efficient than the other mutant strains in the bioconversion
experiments (35% of conversion, Fig. 3A), it was selected
as biocatalyst for further experiments.
Our next goal was to generate acetylated derivatives of
different analogues of 1, which differ from 1 either in the
glycosylation pattern (Fig. 1, compounds 4 to 8) or in the
structure of the aglycone side-chain (Fig. 1, compounds 9
Fig. 2. Scheme showing the glycosylation steps blocked during chromomycin biosynthesis in mutants S. griseus C60GI, C10GII, C10GIII and
C10GIV.
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Fig. 3. HPLC analyses of cultures of S. griseus C10GIV fed with: (A) mithramycin 1; (B) demycarosyl-mithramycin 4; (C)
demycarosyl-3D-b-D-digitoxosyl-mithramycin 5; (D) dideolivosyl-6-b-D-amicetosyl-mithramycin 6; (E)
deoliosyl-demycarosyl-3C-b-D-boivinosyl-mithramycin 7; (F) dideolivosyl-6-b-D-amicetosyl-deoliosyl-3C-b-D-olivosyl-mithramycin 8; (G)
mithramycin SK 9; and (H) mithramycin SDK 10. Acetylated derivatives with one (), two ( ) or three () acetyl groups. Compounds 11 to 17 are
bioconversion products and were purified and characterized (see Fig. 4 for chemical structures).
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and 10). Streptomyces griseus C10GIV was fed with all
these compounds independently and the cultures were
analysed by HPLC and HPLC-MS (Fig. 3B–H). In all the
cases new peaks were detected which corresponded to
monoacetylated derivatives, as deduced from the higher
retention times and masses of the novel compounds,
differing in 42 units in comparison with the respective
substrates. These mass changes are consistent with the
incorporation of a single acetyl group to the compound.
Bioconversions with some compounds led to the forma-
tion of several derivatives with the same mass
(monoacetylated), but with different retention times (com-
pounds 4, 5 and 6 shown in Fig. 3B, C and D), suggesting
that acetylations took place in different positions of the
substrates. Moreover, bioconversions with compounds 4,
5, 7 and 9, and also 1 resulted in the generation of
compounds with mass differing in 84 units from the cor-
responding substrates, being consistent with the genera-
tion of derivatives with two acetyl groups attached
(Fig. 3A, C, E and G). Also, an analogue of compound 5
was obtained with an m/z value in positive mode of 1197
(peak 16 in Fig. 3C), which is consistent with the incorpo-
ration of three acetyl groups to compound 5.
Isolation and structure elucidation of selected
compounds
Some acetylated compounds were selected for purifica-
tion and further characterization. Selection was mainly
based on the antitumour activity of the parental com-
pounds, but also considering the yields and the possible
structural diversity of the acetylated derivatives. In total
we purified seven compounds: one derivative from 1
(compound 11, Fig. 3A), five from 5 (compounds 12 to 16,
Fig. 3C) and one from 9 (compound 17, Fig. 3G). These
compounds were purified by preparative HPLC from cul-
tures of S. griseus C10GIV fed with the corresponding
substrates. The acetylated compounds were initially iden-
tified by HPLC-MS analyses by comparing the UV absor-
tion spectrum and analysing the mass of the molecular
ion. For the new derivative obtained from 1 (compound
11) a molecular formula of C54H78O25 (m/z: 1128) was
deduced, indicating the incorporation of one acetyl group
into the trisaccharide moiety. Similarly, mass spectra of
the five derivatives isolated from 5 revealed three
monoacetylated derivatives (compounds 12 to 14) with a
molecular formula of C53H76O25 (m/z: 1114), one diacety-
lated derivative (compound 15) with a molecular formula
of C56H80O25 (m/z: 1156) and one triacetylated derivative
(compound 16) with a molecular formula of C58H82O26
(m/z: 1198), all of them acetylated in the trisaccharide
chain. The compound 17 isolated from 9 showed a
molecular formula of C53H76O24 (m/z: 1098), indicating the
presence of one acetyl group in the trisaccharide chain
again. Final identification of the novel compounds was
carried out by 1H mono- and bidimensional NMR experi-
ments (COSY, TOCSY) (see Supporting information). The
acetylated positions in the novel analogues were identi-
fied by comparing the corresponding spectra with those
previously described for compounds 1, 5 and 9 (Wohlert
et al., 1999; Remsing et al., 2003; Baig et al., 2008). The
chemical structures of the isolated compounds are shown
in Fig. 4.
These new compounds differ from the parental com-
pounds in the presence of one, two or three acetyl groups
attached at specific positions of different sugars of the
saccharide chains. Three different hydroxyl groups in
mithramycins were susceptible of being acetylated by
CmmA, those located at C3 and C4 of sugar E and the
one at position C4 of sugar D. Acetylation at 3E occurred
when D-digitoxose was the distal sugar of the trisaccha-
ride chain instead of D-mycarose, as it happens in 5; it is
likely that the presence of the C-methyl group at C3 in
D-mycarose prevents the access of CmmA to that posi-
tion. In chromomycins, the 4E hydroxyl group is the most
common acetylated position. On the contrary, no chromo-
mycin has been identified yet with an acetyl group at 3E
(Menéndez et al., 2004b; 2006). Most probably, the exist-
ence of a C-methyl group at C3 in L-chromose B (sugar E)
in 2 would prevent the acetylation event. On the other
hand, 4D position is susceptible to acetylation in mithra-
mycins but not in chromomycins. This could be explained
because sugar D in mithramycins is a D-oliose while in
chromomycins is a D-olivose. These two sugars only differ
in the configuration of the hydroxyl group at C4, axial in
the former and equatorial in the latter, which highlights the
importance of the configuration of that hydroxyl group to
be acetylated. On the contrary, no compound was pro-
duced with acetyl groups in the disaccharide chain of 1 or
its derivatives. This is in contrast to what happens in 2
where the 4A position is normally acetylated, and the 3A
and 4B positions are occasionally acetylated (Menéndez
et al., 2004b). These differences could be also explained
by the different sugar configuration of the disaccharide
chain in both compounds, consisting of D-olivoses in 1
and in some analogues, and D-olioses in 2. In summary,
based on the structures of known chromomycins and
acetylated mithramycin compounds reported in this
article, it seems that CmmA has preference for hydroxyl
groups in axial configuration and not for those in equato-
rial configurations, unless these are located at the third
sugar of the trisaccharide chain; approximately 59% of
acetylated mithramycin compounds obtained by biocon-
version are acetylated at hydroxyl groups in axial configu-
ration, versus 39% in equatorial configuration.
The generation of different types of acetylated mithra-
mycins indicates that CmmA shows substrate acceptor
flexibility, both regarding the position and type of sugar
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Fig. 4. Chemical structures of new acetylated derivatives of (A) mithramycin 1, (B) demycarosyl-3D-b-D-digitoxosyl-mithramycin 5 and (C)
mithramycin SK (9). Acetyl groups are highlighted with circles.
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acetylated and also regarding the structure of the side-
chain of the aglycone. In this respect, we were able to
generate acetylated derivatives of mithramycins indepen-
dently of the structure and length of their side-chain.
Antitumour activity
The antitumour activity of the new mithramycin analogues
was tested against four tumour cell lines (Table 1). Com-
pilation of the average GI50 (50% of growth inhibition)
values showed that all of the compounds were active at
micromolar concentrations and most of them were also
active at 0.1 mM or lower. In general, all compounds were
less active against glioblastoma cancer cells. This was
particularly noticeable for compounds 12 and 15. This
different behaviour could be ascribed to differences in
gene expression patterns that are specific to each cell line
(Ertel et al., 2006). Compound 12 showed improved activ-
ity against colon cancer cells (about five times higher
activity than the parent compound 5). Moreover, com-
pound 14 was particularly active against glioblastoma
cancer cells in relation to its parent compound (activity up
to five times higher than that of compound 5 from which it
derives), and compounds 12, 13 and 16 were better
against pancreas tumour cells (about five times more
active than the parent compound 5). This could be par-
ticularly important since glioblastoma is one of the most
common tumours of the central nervous system, and
despite many efforts to overcome this aggressive disease
the median survival for patients with glioblastoma is only
1 year (Shrieve et al., 1999). On the other hand, the
treatment of pancreatic cancer remains elusive; in spite of
treatment, < 5% of patients remain alive after 5 years
(Chua and Zalcberg, 2008). Therefore, development of
new compounds with high activity against pancreatic
tumours is currently most demanding Interestingly, most
of those mithramycins with improved activities bear one
acetyl group (e.g. compounds 12, 13, 14), but there were
other compounds with two or three acetyl groups (e.g.
compound 16). This indicates that apparently there is no
correlation between the number of acetyl groups and the
antitumour activity.
Localization and in vitro assay of CmmA
In order to in vitro assay CmmA, its coding gene was
subcloned in pEM4T under the control of the erythromycin
resistance promoter (ermE*p) and expressed in Strepto-
myces albus. Correct expression of cmmA in this strain (S.
albus pEM4TCmmA) was verified by carrying out a biocon-
version experiment using as substrate 4A,4E-O-
dideacetylchromomycin A3 3, its natural substrate. This
was readily converted into 2, while a S. albus strain con-
taining an empty vector was unable to carry out that
bioconversion (data not shown). Next, localization of
CmmAin the hyphae was attempted. Mycelia from S. albus
pEM4TCmmA and S. albus pEM4T (as control) were frac-
tionated into soluble and membrane fractions and the
fractions were analysed by Western blotting using anti-
CmmA serum. No positive signals were shown in fractions
from S. albus pEM4T (Fig. 5A). However, positive signals
were detected in the membrane fractions but not in the
soluble fraction of S. albus pEM4TCmmA (Fig. 5A), which
is consistent with the location of CmmA in the cell mem-
brane. These fractions were also tested for acetyltrans-
ferase activity using an in vitro assay. Again, fractions from
the control strain did not shown acetyltransferase activity
(data not shown). However, cell-free extracts and mem-
brane but not soluble fractions from S. albus pEM4TCmmA
were able to acetylate 3 generating 2, in the presence of
acetyl-CoA (Fig. 5B). In this reaction two other compounds
were also produced that could correspond to monoacety-
lated derivatives of 3, since their masses were consistent
with the incorporation of a single acetyl group to 3. These
results clearly demonstrate that CmmA is located and
active in the cell membrane. This location is consistent with
the idea that in the biosynthesis pathway of chromomycin
A3 acetylation of sugars is one of the latest biosynthesis
steps, taking place in close relation to its secretion.
We also tested the possibility of CmmA to use different
donor substrates. We screened short straight- and
branched-chain acyl-CoAs (C3 and C4). Of all acyl-CoA
donors tested only C3 chain acyl-CoAs (isobutyryl- and
propionyl-CoA) were utilized by CmmA, whereas longer-
chain-length acyl-CoAs (isovaleryl-, isobutyryl-CoA and
b-methylcrotonyl-CoA) were not. When isobutyryl-CoA
Table 1. Antitumour activity of compounds.
Tumour cell lines
GI50 (mM)
1 11 5 12 13 14 15 16 9 17
Glioblastoma T98G 0.35 0.22 0.36 1.81 0.34 0.07 1.59 0.31 0.35 0.52
NSCL A549 0.03 0.05 0.06 0.03 0.04 0.03 0.03 0.03 0.02 0.05
Colon H116 0.02 0.01 0.05 0.01 0.03 0.03 0.03 0.02 0.02 0.01
Pancreas PSN1 0.02 0.05 0.05 0.01 0.01 0.02 0.02 0.01 0.02 0.05
GI50, 50% growth inhibition; NSCL, non-small cell lung.
232 B. García et al.
© 2010 The Authors
Journal compilation © 2010 Society for Applied Microbiology and Blackwell Publishing Ltd, Microbial Biotechnology, 4, 226–238
was used, a new peak with a higher retention time and an
m/z value in positive mode of 1169 was produced
(Fig. 6A), which is consistent with the incorporation of an
isobutyryl group to 3. When the donor substrate was
propionyl-CoA, two new compounds were produced that
showed higher retention times than 3 (Fig. 6B), and with
m/z values in positive mode of 1155 and 1211. These
masses were consistent with the incorporation of one and
two propionyl groups to 3 respectively. Propionyl- and
Isobutiryl-CoA were not used with the same efficiency by
CmmA, being the former better substrate than the latter.
As shown in Fig. 6, the use of propionyl-CoA in the reac-
tion led to the complete acylation of compound 3, with the
generation of derivatives with one and two propionyl
groups. However, when isobutiryl-CoA was used approxi-
mately half of compound 3 remained non-acylated
and only one derivative with one isobutiryl group was
generated. Isobutiryl-CoA differs from propionyl-CoA by
the presence of a methyl group at C2, which makes it
bulkier and thus probably interfering in its interaction with
the active site of the enzyme. These experiments demon-
strate that CmmA has some tolerance towards its donor
substrate. CmmA shows similarity to other acyltrans-
ferases involved in tailoring steps of antibiotics biosynthe-
sis. Some of these acyltransferases (MdmB, AcyA and
Asm19) have also shown considerable substrate toler-
ance for the acyl donor, but they were quite specific
towards the acceptor substrate (Hara and Hutchinson,
1992; Arisawa et al., 1994; Moss et al., 2002). On the
contrary, CmmA is also able to acylate different substrates
and at different positions, showing broader acceptor sub-
strate flexibility. This highlights the potential of CmmA as a
tool to create structural diversity and therefore to generate
novel antitumour compounds.
Fig. 5. Localization and in vitro assay of
CmmA.
A. Western analysis of cell-free extracts (CE),
soluble fraction (SF) and membrane fraction
(MF) using anti-CmmA serum. a, control S.
albus (pEM4T); b, S. albus (pEM4TcmmA).
B. Analysis by HPLC of products from
in vitro assays using acetyl-CoA and
4A,4E-O-dideacetyl-chromomycin A3 as
substrates and cell-free extract, soluble
fraction and membrane fraction of S. albus
(pEM4TcmmA) as a source of CmmA.
2, chromomycin A3; 3,
4A,4E-O-dideacetyl-chromomycin A3; ()
monoacetylated derivatives of 3.
Fig. 6. In vitro assays of CmmA using different acyl-CoA donors. Analysis by HPLC of reaction products using membrane fraction,
4A,4E-O-dideacetyl-chromomycin A3 3, and (A) isobutyryl-CoA or (B) propionyl-CoA as acyl-CoA donor substrates.
4A,4E-O-dideacetyl-chromomycin A3 derivatives with one () or two ( ) acyl groups.
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Experimental procedures
Strains, culture conditions, plasmids and DNA
manipulation
Several strains were used as biocatalysts for bioconversion
experiments: S. griseus ssp. griseus ATCC 13273, chromo-
mycin A3 producer, and the S. griseus mutant strains C60GI,
C10GII, G10GIII and G10GIV, each one affected in a glyco-
syltransferase gene of the chromomycin biosynthesis gene
cluster (Fig. 2) (Menéndez et al., 2006). Streptomyces albus
J1074 (ilv-1, sal-2; Kieser et al., 2000) was used as host for
expression of cmmA. Several S. griseus and S. argillaceus
recombinant strains were used to prepare substrates for bio-
conversion experiments and enzyme assays (see Fig. 1): S.
griseus C10A to produce 3 (Menéndez et al., 2004b); S.
argillaceus ATCC12956 for 1; S. argillaceus (pMP3*BII) for 4
and 5; S. argillaceus (pFL845) for 6; S. argillaceus (pMP1*BII)
for 7; S. argillaceus M7U1 (pFL845) for 8 (Baig et al., 2008;
Pérez et al., 2008); and S. argillaceus M7W1 for 9 and 10
(Remsing et al., 2003; Albertini et al., 2006). For sporulation
on solid medium, the organisms were grown at 30°C on plates
containing A medium (Fernández et al., 1998), supplemented
with 25 mg ml-1 thiostrepton when appropriate. For growth in
liquid medium, the organisms were grown either in TSB
medium (trypticase soya broth; Oxoid) or in R5A medium
(Fernández et al., 1998), supplemented with 5 mg ml-1 thios-
trepton when appropriate. pEM4T was used for expressing
genes in Streptomyces (Menéndez et al., 2006). Escherichia
coli DH10B (Invitrogen) was used as a host for subcloning.
Plasmid pQE60CmmA was used as source of cmmA (N.
Menéndez, unpublished). DNAmanipulations were performed
according to standard techniques for E. coli (Sambrook and
Russell, 2001) and Streptomyces (Kieser et al., 2000).
PCR amplification and gene expression
For amplification of cmmA, pQE60cmmA was used as DNA
template and the following oligoprimers: 5′-GGACTAGTCC
TAGGGGACGAAAGAGGCAGGATG-3′ (SpeI and AvrII sites
underlined) and 5′-GCTCTAGATCAGTGGTGGTGGTGGT
GGTG-3′ (XbaI site underlined). PCR conditions were as
follows: 100 ng of template DNA was mixed with 30 pmol of
each primer and 1.25 units of Pfx DNA polymerase (Invitro-
gen) in a total reaction volume of 50 ml containing 2 mM each
dNTP, 10 mM KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH
8.8), 2 mM MgSO4 and 0.1% Triton X-100. The polymeriza-
tion reaction was performed in a thermocycler (MiniCycler;
MJ Research) under the following conditions: an initial dena-
turation of 2 min at 94°C; 30 cycles of 15 s at 94°C, 30 s at
55°C and 1 min at 68°C; after the 30 cycles, an extra exten-
sion step of 5 min at 68°C and another of 15 min at 4°C were
added. After PCR amplification, the amplicon containing
cmmA was digested with SpeI and XbaI, treated with Klenow
polymerase and subcloned into the EcoRI site pre-treated
with Klenow polymerase of pEM4T. In the resultant plasmid
(pEM4TcmmA), cmmA is under the control of the ermE*p.
Bioconversion experiments
Streptomyces griseus wild type or the appropriate mutant
strain was cultivated in TSB liquid medium with shaking at
30°C for 24 h. One hundred microlitres of the resultant cul-
tures were used as pre-inoculum to inoculate Erlenmeyer
flasks containing 5 ml of R5A liquid medium. After 24 h of
incubation, 15 mg per ml of the substrate (final concentration)
was added, and further incubation was carried out for 24 h. In
the case of mutants S. griseus C10GIII and S. griseus
C10GIV, cultures were supplemented with 2 mg ml-1 2 (final
concentration) in order to induce expression of chromomycin
biosynthesis genes (Menéndez et al., 2006). After incubation,
samples (1 ml) were extracted with 1 volume of ethyl acetate:
formic acid (100:1). Organic extracts were dried under
vacuum, and residues were eventually dissolved in a small
volume of methanol before HPLC analysis.
HPLC analysis and purification of novel compounds
Chromatographic analyses were performed by HPLC-MS as
previously described (Olano et al., 2009), except that bidi-
mensional chromatograms were extracted at 280 nm. Acety-
lated derivatives were obtained in bioconversion experiments
in R5A medium supplemented with 15 mg ml-1 of the precur-
sor molecule. Approximately 1.2 l of culture was prepared to
obtain 4E-O-acetyl-mithramycin 11, whereas the derivatives
of 5 were obtained from 5 l of culture. In both cases, the
cultures were centrifuged and the supernatants were filtered
and applied to a solid-phase extraction cartridge (Sep-Pak
Vac C18, 10 g, Waters). The retained material was eluted
with a mixture of methanol and 0.05% trifluoroacetic acid
(TFA) in water. A linear gradient from 0 to 100% methanol in
60 min, at 10 ml min-1, was used. Fractions were taken every
5 min and analysed by UPLC. Fractions containing the
desired compounds were neutralized with 3 ml of 0.1 M phos-
phate buffer (pH 7.0) and evaporated in vacuo. The resulting
extracts were redissolved in a small volume of a mixture of
DMSO and methanol (50:50) and the products were purified
by preparative HPLC using a SunFire C18 column
(10 ¥ 250 mm, Waters). Compounds were chromatographed
with mixtures of acetonitrile or methanol and 0.05% TFA in
water, in isocratic conditions optimized for each peak, at
7 ml min-1. During all purification steps, the peaks were col-
lected on 0.1 M phosphate buffer (pH 7.0). The solutions
obtained were partially evaporated in rotavapour to reduce
the concentration of the organic solvent and then applied to a
solid-phase extraction cartridge (Sep-Pak Vac C18, Waters),
washed with water to remove salts, eluted with methanol and
finally lyophilized.
An alternative method was carried out for the purification of
4D-O-acetyl-mithramycin SK 17. In this case, 2 l of R5A
medium for the bioconversion experiment was supplemented
with 50 mg ml-1 of the precursor molecule. The culture was
centrifuged and the supernatant was filtered and solid-phase
extracted (Sep-Pak Vac C18, 10 g, Waters). A linear gradient
of methanol and water (0–100% methanol during 60 min at
10 ml min-1) was applied for elution of the retained material.
Fractions obtained were analysed by HPLC and those con-
taining the acetylated derivative were pooled and dried in
vacuo. The extract was redissolved in 5 ml of methanol and
the purification procedure was carried out in a preparative
column (XBridgeTM Prep C18, 5 mm, 30 ¥ 150 mm, Waters)
with isocratic elution using MeCN and 0.1% TFA in water
(45:55), at 20 ml min-1. As TFA was used in the mobile phase
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of the purification, the peak was collected on 0.1 M potassium
phosphate buffer (pH 7.0) and diluted fourfold with water to
be desalted and concentrated by solid-phase extraction,
being finally lyophilized. The yields for the different com-
pounds were as follows: 3.1 mg of 11; 1.7 mg of 12; 4.6 mg of
13; 1.0 mg of 14; 1.8 mg of 15; 2.5 mg of 16; and 5.2 mg of
17.
Structure elucidation and characterization of new
mithramycin derivatives
The structures of the new mithramycin analogues were elu-
cidated by NMR spectroscopy, employing 1D 1H, 13C and
homonuclear 2D 1H COSY/TOCSY experiments. All NMR
data were recorded in acetone-d6 at 298 K using a Bruker
Avance Ultrashield Plus 600 spectrometer (600 MHz for 1H,
150 MHz for 13C experiments). Typical parameters for 2D
experiments were: COSY/TOCSY, 256 and 2048 points in F1
and F2, respectively, 48 transients each. NMR experiments
were processed using the program Topspin 1.3 (Bruker
GmbH, Karlsruhe, Germany).
Determination of antitumour activity
The antitumour activity of the mithramycin derivatives was
tested against four tumour cell lines. Quantitative measure-
ment of cell growth and viability was carried out using the
MTT tetrazolium assay (Mosmann, 1983). Values correspond
to the average of three independent assays.
Cell fractionation
To determine the location of the CmmA protein, S. albus
pEM4TcmmA was grown in TSB medium at 30°C with orbital
shaking for 48 h. Cultures were centrifuged and the mycelium
was washed twice with 50 mM Tris-HCl (pH 7.5), 1 mM EDTA
and 20% glycerol. The mycelium was disrupted by two
passes through a French press at a pressure of 10.3 MPa.
DNA was broken by ultrasound (six pulses of 15 s each with
intermittent cooling on ice water) in a MSE ultrasonic disin-
tegrator at 150 watts and 50 kHz. Unbroken cells and debris
were removed by centrifugation at 12 000 g for 30 min.
Samples were collected from the resultant supernatant and
were named ‘cell-free extracts’. The supernatant was further
centrifuged at 69 000 g for 1 h. The resulting supernatant was
designated ‘soluble fraction’. The pellet containing the cell
membranes was resuspended in a small volume of the
above-mentioned buffer and was named ‘membrane frac-
tion’. Protein estimation in the different samples was carried
out by measurement of absorbance at 540 nm by a protein-
dye binding assay using bovine serum albumin as standard
(Bradford, 1976).
Polyacrylamide gel electrophoresis and Western
analysis
Protein analysis was carried out by polyacrylamide gel elec-
trophoresis in the presence of SDS (Laemmli, 1970). Western
blotting was performed as described (Burnette, 1981), using
the developing kit ECL plus Western Blotting Detection
System (Amersham Biosciences). A peptide (ARPGDSTRS-
FYRRC) corresponding to the second predicted cytoplasmic
loop of CmmA was synthesized to produce anti-CmmA serum
(SigmaGenosys).
In vitro assays of CmmA
Acetylation assays were conducted in a total volume of 50 ml
in Tris-HCl 50 mM pH 8, EDTA 1 mM and glycerol 20%,
including 100 mM 3, 130 mg of protein from the membrane
fraction (or the corresponding cell fraction to be tested) and
500 mM acetyl-CoA. After incubation at 30°C for 2 h, the
reaction products were extracted twice with 50 ml of ethyl
acetate acidified with 3 ml of 0.4 N HCl. After phase separa-
tion, the organic phase was recovered, the solvent evapo-
rated and the residue were suspended in 50 ml of methanol
prior analysed by HPLC. Assays were also carried out using
other acyl-CoA donors (2 mM final concentration): isovaleryl-
CoA, isobutyryl-CoA, b-methylcrotonyl-CoA, propionyl-CoA
and succinyl-CoA.
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